レンツ・セラピューティクス
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.02 | $5M | -$39M |
| 2026 Q1 | -1.32 | $2M | -$34M |
| 2025 Q4 | -1.16 | $2M | -$33M |
| 2025 Q3 | -0.59 | $13M | -$9M |
| 2025 Q2 | -0.53 | $5M | -$12M |
| 2025 Q1 | -0.53 | $0 | -$16M |
| 2024 Q4 |
| -0.46 |
| $0 |
| -$9M |
| 2024 Q3 | -0.38 | $0 | -$11M |